Research
Hormonal
Bariatric surgery improves cardiovascular risk profiles by significantly altering adipokine secretion profiles, specifically decreasing leptin and increasing adiponectin, independent of simple caloric restriction.
Bariatric surgery is effective not just because it reduces stomach size, but because it fundamentally changes the hormones your fat cells release. It lowers leptin (reducing resistance) and raises adiponectin (improving insulin sensitivity and reducing inflammation), which collectively improve cardiovascular risk.
GoodSupportsHIGH confidence
Leptin decreases and its physiology is restored after bariatric surgery... Bariatric surgery induced weight-loss and induced sustained increases in adiponectin plasmatic levels in parallel with the whole improvement of the metabolic profile, and the decrease in leptin levels observed post-surgically.
Why this rating
The paper cites multiple studies ([51, 52, 57]) showing consistent improvements in adipokine levels post-surgery.
Source
Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk
Manuel F. Landecho et al. · Nutrients · 2019
DOI 10.3390/nu11112664
narrative_reviewCited 300×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity-associated cardiovascular risk is driven by adipose tissue dysfunction and altered adipokine secretion (specifically increased leptin/resistin and decreased adiponectin/omentin-1), rather than body mass index (BMI) alone.Good
- Leptin resistance in obesity reverses its protective vascular effects, contributing to a pro-oxidative state, endothelial dysfunction, and accelerated biological senescence.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →